Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Low acylation stimulating protein levels are associated with cardiometabolic disorders-secondary to autoimmune activation?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: KARE publishing Country of Publication: Turkey NLM ID: 101652981 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2149-2271 (Electronic) Linking ISSN: 21492263 NLM ISO Abbreviation: Anatol J Cardiol Subsets: MEDLINE
    • بيانات النشر:
      Publication: 2023- : İstanbul, Turkey : KARE publishing
      Original Publication: İstanbul, Turkey : Aves, [2015]-
    • الموضوع:
      Complement C3a/*metabolism ; Metabolic Syndrome/*epidemiology; 1-Alkyl-2-acetylglycerophosphocholine Esterase/blood ; Autoimmunity ; Cross-Sectional Studies ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/immunology ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Logistic Models ; Male ; Metabolic Syndrome/blood ; Metabolic Syndrome/immunology ; Middle Aged ; Prevalence ; Prospective Studies ; Turkey/epidemiology
    • نبذة مختصرة :
      Objective: We investigated the possible association of serum acylation stimulating protein (ASP) with cardiometabolic disorders and the evidence of autoimmune activation.
      Methods: Population-based randomly selected 1024 participants were cross-sectionally and prospectively analyzed. ASP concentrations were measured with a validated ELISA kit. Correlations were sought separately in subjects with no cardiometabolic disorders (n=427) designated as "healthy."
      Results: ASP was positively correlated with total testosterone and inversely correlated with platelet activating factor (PAF), PAF-acetylhydrolase (AH), in each gender, and positively correlated in "healthy" men with lipoprotein [Lp](a) and apolipoprotein B. Correlations of ASP with PAF values ≥22 nmol/L were abolished, contrasted to a strongly inverse one in subjects with PAF <22 nmol/L. In linear regression analyses in the whole sample, ASP was inversely associated independently with PAF and PAF-AH and, in men, positively with Lp(a) and sex hormone-binding globulin. Prevalent and (at 2.0 years' follow-up) incident metabolic syndrome (MetS, n=393), diabetes (n=154), and coronary heart disease (CHD, n=171) were analyzed by sex-, age-, and Lp(a)-adjusted logistic regression, using tertiles of ASP and PAF. The lower two (<42 nmol/L) ASP tertiles were a risk factor in combined sexes for MetS and diabetes. In women, incident CHD was predicted by either reduced or elevated ASP tertiles.
      Conclusion: Findings can be explained by the notion of operation of immune responses against both ASP and oxidized PAF-like lipids of Lp(a) to yield for "reduced" values and increased likelihood of cardiometabolic disorders.
    • References:
      Gynecol Endocrinol. 2007 Dec;23(12):710-5. (PMID: 18075846)
      Curr Opin Lipidol. 2013 Oct;24(5):426-37. (PMID: 23995232)
      Fertil Steril. 2009 Jan;91(1):213-9. (PMID: 18206145)
      Annu Rev Biochem. 2000;69:419-45. (PMID: 10966465)
      Clin Chim Acta. 2011 Jun 11;412(13-14):1171-9. (PMID: 21419112)
      J Clin Endocrinol Metab. 2001 Aug;86(8):3659-64. (PMID: 11502793)
      Am J Gastroenterol. 2005 Apr;100(4):842-9. (PMID: 15784030)
      Circulation. 2004 Jan 27;109(3):433-8. (PMID: 14744958)
      Clin Endocrinol (Oxf). 2009 Apr;70(4):539-46. (PMID: 18702682)
      Biochem Pharmacol. 2003 Dec 1;66(11):2069-73. (PMID: 14609731)
      Vascul Pharmacol. 2002 Apr;38(4):193-200. (PMID: 12449015)
      Atherosclerosis. 2001 May;156(1):1-10. (PMID: 11368991)
      Obes Res. 1999 Sep;7(5):444-52. (PMID: 10509601)
      Exp Clin Endocrinol Diabetes. 2015 Jan;123(1):11-8. (PMID: 25314652)
      J Investig Med. 2016 Feb;64(2):392-9. (PMID: 26911630)
      Am J Cardiol. 2008 Jun 16;101(12A):23F-33F. (PMID: 18549868)
      Pediatr Nephrol. 2008 Jun;23(6):959-64. (PMID: 18253759)
      JAMA. 2009 Jul 22;302(4):412-23. (PMID: 19622820)
      Diabetes Care. 2003 Nov;26(11):3160-7. (PMID: 14578255)
      Eur J Clin Invest. 1999 Aug;29(8):679-86. (PMID: 10457151)
      ISRN Obes. 2013 Feb 12;2013:342802. (PMID: 24533222)
      Biochim Biophys Acta. 2006 Nov;1761(11):1359-72. (PMID: 17049457)
      Biochim Biophys Acta. 2003 Jan 31;1609(2):127-43. (PMID: 12543373)
      Int J Obes (Lond). 2006 Mar;30(3):439-46. (PMID: 16302015)
      Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2523-9. (PMID: 16960105)
      J Epidemiol Community Health. 1992 Oct;46(5):470-6. (PMID: 1479313)
      Diabetol Metab Syndr. 2015 Dec 02;7:110. (PMID: 26633998)
      Mem Inst Oswaldo Cruz. 2005 Mar;100 Suppl 1:83-91. (PMID: 15962103)
      Curr Pharm Des. 2014;20(4):575-84. (PMID: 23565630)
      Cardiovasc Drugs Ther. 2009 Feb;23(1):73-83. (PMID: 18949548)
      PLoS One. 2012;7(10):e46883. (PMID: 23056509)
      Atherosclerosis. 2007 Mar;191(1):182-90. (PMID: 16678831)
    • الرقم المعرف:
      0 (complement C3a, des-Arg-(77)-)
      80295-42-7 (Complement C3a)
      EC 3.1.1.47 (1-Alkyl-2-acetylglycerophosphocholine Esterase)
      EC 3.1.1.47 (PLA2G7 protein, human)
    • الموضوع:
      Date Created: 20160908 Date Completed: 20190408 Latest Revision: 20190408
    • الموضوع:
      20231215
    • الرقم المعرف:
      PMC5336773
    • الرقم المعرف:
      10.14744/AnatolJCardiol.2016.7024
    • الرقم المعرف:
      27599666